Oric Pharmaceuticals, Inc. has sold 13,478,432 shares under the program for gross proceeds of approximately $139.7 million. The new supplement replaces the one from March 2024.
ORIC expects a one-time cost of approximately $1.9 million for the workforce reduction. The company says cash and investments should fund its revised operating plan into 2H 2028, helped by $244 million in gross proceeds.
The company ended discovery research to focus on ORIC-944 and enozertinib. It does not expect to use its at-the-market facility for the foreseeable future.
ORIC Pharmaceuticals agreed to sell about 19.2 million shares or pre-funded warrants at $6.50 in a private placement with roughly $125 million in gross proceeds. The company says the cash funds operations into the second half of 2027, a runway tied to a Phase 3 readout it has not yet reported.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $37.5 million, plus short-term investments of $227.3 million, $264.8 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Oric Pharmaceuticals
Has Oric Pharmaceuticals raised money recently?
Our latest story on this, dated Feb 23, 2026: "Oric Pharmaceuticals files new $200.0 million at-the-market prospectus with Jefferies". The story links the filing or release it is based on. Read the story.
Has Oric Pharmaceuticals cut staff?
Our latest story on this, dated Aug 12, 2025: "ORIC cuts 20% of staff after $244 million gross financing, expects runway into 2028". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Oric Pharmaceuticals?
Oric Pharmaceuticals, Inc. trades under the ticker ORIC on NASDAQ.
Where is Oric Pharmaceuticals listed?
Oric Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:4TZ; LSX:A2P208.
What is the SEC CIK of Oric Pharmaceuticals?
The SEC Central Index Key (CIK) for Oric Pharmaceuticals, Inc. is 1796280. Its filings are on SEC EDGAR.
How many shares does Oric Pharmaceuticals have outstanding?
103,652,656 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-08-03.
Which country or territory is Oric Pharmaceuticals listed under?
Our directory records Oric Pharmaceuticals, Inc. under United States.
What does Oric Pharmaceuticals do?
Our directory classifies Oric Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Oric Pharmaceuticals?
The ISIN recorded for Oric Pharmaceuticals, Inc. is US68622P1093.
Does aibio.space cover Oric Pharmaceuticals?
aibio.space lists Oric Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Oric Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
Is Oric Pharmaceuticals profitable?
Oric Pharmaceuticals, Inc. reported a net loss of $129.5 million for the fiscal year ended Dec 31, 2025, and used $111.0 million of cash in operations, per its annual report to the SEC.
How much does Oric Pharmaceuticals spend on research and development?
$109.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Oric Pharmaceuticals have?
$264.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Oric Pharmaceuticals (ORIC) stock news?
Our latest story on Oric Pharmaceuticals, dated Feb 23, 2026: "Oric Pharmaceuticals files new $200.0 million at-the-market prospectus with Jefferies". Oric Pharmaceuticals, Inc. has sold 13,478,432 shares under the program for gross proceeds of approximately $139.7 million. The new supplement replaces the one from March 2024. Source.
Investor discussion: Oric Pharmaceuticals
Members talk about Oric Pharmaceuticals (ORIC). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Oric Pharmaceuticals, newest first. Each line links the filing it comes from.
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ORIC on TradingView.
SEC filings and registration
SEC name
Oric Pharmaceuticals, Inc.
CIK
1796280
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
ORIC (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer
Business address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080
Phone
(650) 388-5600
Shares outstanding
103,652,656 as of 2026-07-27 (10-Q filed 2026-08-03)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Oric Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ORIC, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio